GF50816998
Ruthenium
Ruthenium, bar, 50mm x 2mm x 2mm, 99.9%
Sign Into View Organizational & Contract Pricing
All Photos(2)
Ruthenium, RU008010
Ru
Recommended Products
Assay
99.9%
form
foil
manufacturer/tradename
Goodfellow 508-169-98
resistivity
7.1 μΩ-cm, 0°C
L × W × thickness
50 mm × 2.0 mm × 2.0 mm
bp
3900 °C (lit.)
mp
2310 °C (lit.)
density
12.45 g/cm3 (lit.)
SMILES string
[Ru]
InChI
1S/Ru
InChI key
KJTLSVCANCCWHF-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
General description
For updated SDS information please visit www.goodfellow.com.
Legal Information
Product of Goodfellow
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Topics in current chemistry, 292, 211-229 (2010-01-01)
Stoichiometric cycloruthenation reactions of substrates containing Lewis-basic functionalities set the stage for efficient ruthenium-catalyzed C-H bond functionalization reactions. Thereby, selective addition reactions of C-H bonds across alkenes or alkynes enabled atom-economical synthesis of substituted arenes. More recently, ruthenium-catalyzed direct arylation
Accounts of chemical research, 44(4), 289-298 (2011-03-03)
Nitric oxide (NO) can induce apoptosis (programmed cell death) at micromolar or higher doses. Although cell death via NO-induced apoptosis has been studied quite extensively, the targeted delivery of such doses of NO to infected or malignant tissues has not
Current topics in medicinal chemistry, 11(21), 2688-2702 (2011-11-02)
Polynuclear compounds are a relatively new and successful approach in metal-based cancer chemotherapy as typified by the trinuclear Pt compound BBR3464 which was evaluated in clinical trials. In this review, we discuss newer developments of polynuclear ruthenium, osmium and gold
Journal of inorganic biochemistry, 106(1), 90-99 (2011-11-25)
The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with
Metallomics : integrated biometal science, 1(6), 458-470 (2009-11-01)
Interest in Ru anticancer drugs has been growing rapidly since NAMI-A ((ImH(+))[Ru(III)Cl(4)(Im)(S-dmso)], where Im = imidazole and S-dmso = S-bound dimethylsulfoxide) or KP1019 ((IndH(+))[Ru(III)Cl(4)(Ind)(2)], where Ind = indazole) have successfully completed phase I clinical trials and an array of other
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service